COVID-19 Vaccines Return Up to $809 Per Dollar
A 173-country study finds early vaccine access drove the largest health and economic gains.
Updated on Nov. 6, 2026 in COVID-19
Live Poll
Should your government keep funding costly vaccine research during future global health emergencies?
A study of 173 countries found COVID-19 vaccines returned between USD 60 and USD 809 in economic benefit for every dollar invested. The health and economic benefits were valued between USD 6.43 trillion and USD 64.3 trillion, against worldwide development and delivery costs of USD 79.4 billion.
Why it matters
The findings put a price on the global vaccine effort and show that the benefits were distributed unevenly, with high-income countries gaining the most. For readers, it underscores how early access to a vaccine shapes both health outcomes and economic recovery.
Researchers compared the cost of developing, manufacturing and delivering COVID-19 vaccines with years of life gained, quality of life, work productivity and averted health care costs across 173 countries. The return ranged from USD 60 to USD 809 per dollar, and the study was published in PLOS Medicine.
The players
PLOS Medicine
A peer-reviewed medical journal that published the study comparing vaccine costs with health and economic benefits.
London School of Hygiene and Tropical Medicine
A London-based institution known for research in global public health and infectious disease, one of three institutions behind the study.
Imperial College London
A leading research university whose faculty have studied infectious disease modeling, and a co-author institution on this study.
New York University
A research university whose public health researchers contributed to this global analysis of vaccine returns.
The details
The researchers set vaccine development, manufacturing and delivery costs against measured health and economic gains, including life years, quality of life, productivity and averted health care spending. Low-income countries showed the highest averted health care and productivity costs relative to their own economies and populations. High-income countries gained the most economically, reflecting earlier access, higher uptake, faster rollouts and older populations at greater risk of severe disease.
Timeline
Many low- and middle-income countries did not gain widespread vaccine access until late 2021.
The economic return was measured against the first year of vaccine rollout.
Health Landscape
The study places COVID-19 vaccination within the broader history of pandemic response, where early containment and access have repeatedly determined outcomes. It quantifies a pattern that public health researchers have long argued but that rarely gets measured across so many countries at once.
The findings reinforce that timely vaccination has measurable health and economic value at the population level. If you have questions about your own vaccination status or booster timing, that is worth discussing with your doctor.
The takeaway
Vaccination produced large returns on investment across income groups, with the greatest gains where access came early. Staying current with recommended vaccines is a practical step, and your physician can help you review what applies to you.
Further reading
For more on the pandemic's global toll and response, see the COVID-19 section.
Source note: This article includes information reported by Economic Times.
Live Poll
Should your government keep funding costly vaccine research during future global health emergencies?
